Recent health news highlights financial and strategic developments in major pharmaceutical companies like Gilead and Merck, ...

Gilead Sciences reports profits but mixed revenue; Merck is in talks to acquire SpringWorks for $3.5 billion; measles cases ...

Gilead Sciences (NASDAQ: GILD) didn't have a bad first quarter, but investors didn't find it inspiring either. After ...

The company is looking to the highly anticipated launch of a closely watched HIV medicine to offset weakening demand for ...

Summer is creeping closer, and for Gilead Sciences that only means one thing: the much-anticipated launch of long-acting HIV ...

Gilead Sciences' Q1 2025 earnings reveal challenges in oncology and Veklury sales, while HIV therapies remain strong. See why ...

The company's first-quarter revenue slipped 0.3% year-over-year to $6.67 billion, while analysts surveyed by Visible Alpha ...

Despite steep budget and staffing cuts at the FDA in recent weeks and other headwinds, Gilead CEO Daniel O’Day assured investors that the pharma’s plans and preparations for lenacapavir’s launch ...

Gilead’s HIV drug business grew while its Covid drug sales tanked in the first quarter of 2025, as the company recorded the ...

Gilead Sciences, Inc. ( NASDAQ: GILD) Q1 2025 Earnings Conference Call April 24, 2025 4:30 PM ET Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial ...

The Motley Fool. DATE Thursday, Apr 24, 2025 Read More: Earn up to $845 cash back this year just by changing how you pay at Costco! Learn more here. CALL PARTICIPANTS Daniel O'Day: Chairman and Chief ...

Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...